Jiva.ai joins P4 Precision Medicine Class of 2020

22 Mar Jiva.ai joins P4 Precision Medicine Class of 2020

Posted at 18:38h in News by Jiva AI

Press Release

Jiva has been accepted on another great accelerator: P4 Precision Medicine.

The program seeks the worlds leading Precision Medicine startups to support through development, regulation, investment, adoption and scale to UK and international markets to innovate and advance the healthcare landscape. It curates an ecosystem of physical space and specialist to support precision medicine innovations to develop research into world leading technology, support to gain regulatory approval and adoption not only to the UK healthcare system but scale internationally.

Entry into this program comes at an interesting time in the company’s journey: not only is Jiva about to open its second round of funding, but the country is in the grip of a global pandemic. We have no doubt that our participation in this program will solidify our position in the marketplace as an exciting, innovative company that can weather the pending storm and make a positive, palpable impact to healthcare.

Jiva AI

admin@jiva.ai

Latest News

Emerging AI Safety Regulation

The first major international AI Safety Summit hosted by the UK earlier this month marked a significant milestone in the global conversation about the safe development of frontier artificial intelligence (AI). Over the course of two days, 150 representatives from around the world, including government......

27 November, 2023

Jiva.ai wins Innovate UK funding for Advanced Diagnostics Innovation Programme

Summary Jiva.ai in collaboration with the University of Manchester and others, have been awarded part of a £5.5m Innovate UK grant on behalf of UKRI, to advance the use of novel diagnostics across Greater Manchester. The project is part of a cohort of 7 projects......

22 November, 2023

In the Wake of OpenAI’s Turbulence: Rethinking the Foundation of AI Integration

The recent upheaval in the AI industry, marked by the surprising removal and potential rehiring of Sam Altman as CEO at OpenAI, has sent shockwaves through businesses relying on the paid version of GPT as a linchpin in their products or internal operations. This unexpected......